EVFM (Evofem Biosciences) FCF Margin %: 255.73% (As of Mar. 2026)


What is Evofem Biosciences FCF Margin %?

Evofem Biosciences EVFM -0.06% FCF Margin % is 255.73% as of Mar. 2026. The stock has 5 warning signs investors should review. Among 960 Biotechnology companies, Evofem Biosciences ranks better than 73.96% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Evofem Biosciences's Free Cash Flow for the three months ended in Mar. 2026 was $2.30 Mil. Evofem Biosciences's Revenue for the three months ended in Mar. 2026 was $0.90 Mil. Therefore, Evofem Biosciences's FCF Margin % for the quarter that ended in Mar. 2026 was 255.73%.

As of today, Evofem Biosciences's current FCF Yield % is -21.89%.

The historical rank and industry rank for Evofem Biosciences's FCF Margin % or its related term are showing as below:

EVFM' s FCF Margin % Range Over the Past 10 Years
Min: -24009.64   Med: -234.73   Max: -1.25
Current: -1.25

During the past 13 years, the highest FCF Margin % of Evofem Biosciences was -1.25%. The lowest was -24009.64%. And the median was -234.73%.

EVFM's FCF Margin % is ranked better than
73.96% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs EVFM: -1.25

Evofem Biosciences FCF Margin % Related Terms

Evofem Biosciences FCF Margin % Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences FCF Margin % Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,814.73 -420.21 -49.25 -20.14 -9.89

Evofem Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.27 -60.50 6.79 0.32 255.73

EVFM vs PTIX, ATXI, AGTX: FCF Margin % Comparison

For the Biotechnology subindustry, Evofem Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evofem Biosciences FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's FCF Margin % falls into.


Evofem Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Evofem Biosciences's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.997/20.183
=-9.89 %

Evofem Biosciences's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=2.299/0.899
=255.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 255.73% mean?
Evofem Biosciences (EVFM) has a FCF Margin % of 255.73% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Evofem Biosciences and its competitors. According to the industry distribution chart, Evofem Biosciences ranks #250 out of 960 companies in the Biotechnology industry, placing it in the top 26%.
Is Evofem Biosciences' FCF Margin % too high?
Evofem Biosciences' current FCF Margin % is 255.73%. Based on the distribution chart, Evofem Biosciences ranks #250 out of 960 companies in the Biotechnology industry, which is above the industry midpoint.
How does Evofem Biosciences' FCF Margin % compare to PTIX and ATXI?
According to the Biotechnology industry distribution chart, Evofem Biosciences ranks #250 out of 960 companies for FCF Margin %. This puts Evofem Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current FCF Margin % is 255.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12.8% below its estimated fair value. The current FCF Margin % is 255.73%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current FCF Margin % is 255.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.